MAPS PBC Announces Submission of New Drug Application to the FDA for MDMA-Assisted Therapy for PTSD kptv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kptv.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Aruvant, a clinical-stage biopharmaceutical company focused on developing and commercializing transformative gene therapies for the treatment.
Share this article
Share this article
NEW YORK and BASEL, Switzerland, April 23, 2021 /PRNewswire/ Aruvant Sciences ( Aruvant ), a private company focused on developing gene therapies for rare diseases, today announced the appointment of Meghan Kelton, executive director, human resources (HR), and E. Blair Clark-Schoeb, senior vice president, communications, to the Aruvant leadership team. Ms. Kelton s HR experience in gene therapy and Ms. Clark-Schoeb s public company and rare disease communications know-how will be critical as we take Aruvant to the next level, said Will Chou, M.D., chief executive officer of Aruvant. With the company in a growth phase, Ms. Kelton will focus on building out the technical, development and manufacturing functions and creating an inclusive environment needed to support an engaged workforce. Ms. Clark-Schoeb will lead our internal and external communications efforts, investor relations, media effort and work with the rare disease and sick